Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample. The QIAseq Multimodal DNA/RNA Lib Kit facilitates multiomics, the ...

You don't need to buy her picks, but it's worth understanding them. Cathie Wood's commitment to buying shares of businesses working on disruptive innovations, via her ARK Innovation ETF and ARK Genomic Revolution ETF, makes her investing style very much on the riskier side of the spectrum -- especially when she invests in already risky areas like biotech. But if her theses are correct, the upside to investors could be tremendous, assuming they can tolerate what might be a very long and bumpy ride between bu ...

It needs to work within the constraints imposed by these three issues. Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (DNA 0.70%) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those plans would make it a smart stock to own as well. But for now, it's still trying to find its footing, and it's a riskier bet than investors may realize. So without further ado, here ...

Reasons to buy Ginkgo Bioworks The company's cell engineering platform combines robotics and artificial intelligence (AI) to produce new cell lines for its clients. This is important because many top-selling drugs are manufactured by genetically modified cells that produce a specific protein. Disrupting the biopharmaceutical manufacturing industry could be extremely lucrative and it isn't the only way Ginkgo's cell engineering platform can earn money. For example, it recently partnered with plant-biotech co ...

Is Ginkgo stock a sell? Although possessing enough cash to keep it going for about two years at its current burn rate, I'm just not sure this company is going anywhere fast. To me, that makes Ginkgo stock a sell. Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Massaro is most concerned with management commentary that new "cell programs" -- of which the company expects to add 100 this year -- are no longer a great forecaster of revenue growth, and may give investors a false ...

Can this struggling stock turn things around? Ginkgo Bioworks (DNA -3.98%) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the problem is it may take more than a decade for those markets to reach that kind of size. Investors could require a lot of patience. While there may be a lot of potential for the business in the long run, investors ...

A few enterprising businesses are marketing themselves differently. As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (DNA 2.63%), Recursion Pharmaceuticals (RXRX 6.01%), and Schrödinger (SDGR 0.30%) could easily be described by the term, and some, like Recursion, even describe themselves that way. But what does this new term ...

BOSTON, May 15, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that management will be participating in two investor conferences in May. Further details, webcast links, and a replay of the presentations, fireside chats, and panels, if available, will be posted on the company's investor relations website at investors.ginkgobioworks.com. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for c ...

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy Ena Cratsenburg, Chief Business Officer, Ginkgo: "We're thrilled to join efforts with Sojitz and collaborate on bolstering the Japanese bioeconomy. Sojitz is a well respected trading company that has extensive relationships with many of the major industrial and chemical companies in Japan. We look forward to working with Japanese companies to leverage our synthetic biology platform to accele ...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2024 Earnings Conference Call May 9, 2024 5:30 PM ET Company Participants Megan LeDuc – Manager-Investor Relations Jason Kelly - Co-Founder & Chief Executive Officer Mark Dmytruk - Chief Financial Officer Conference Call Participants Rahul Sarugaser - Raymond James Matt Sykes - Goldman Sachs Mike Ryskin - Bank of America Steve Mah - TD Cowen Megan LeDuc Good evening, IÂ'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. IÂ'm joined by Jason Kelly, o ...